Member Info for KUMS

very bullish again today as USA is in a mess. Expecting $1300 in few months as gold has already seen $1242 today.

again to 20.25p

of trade has picked up today. Should increase more as each day passes in Q1.

purchase just gone thro!

Next wave will come to take this to 4p.

paid.

In Dec saw the sp & thought of getting in @ 9p. Money was locked elsewhere & so could not. Now 17.75p! Just painful & looks like could get worse if I did not act. So finally in as Gold is on the rise! $1240 now Gold!

Good morning all. I started buying back at 2p & currently added more near 3p on the drop. So lot of money invested as well. From the trades I have been seeing, big buyers( they must have their homework as well) are buying up stock & that's what I have followed & am doing quite well therefore. Thanks Thelix for your posts.

with today's rise. So those in early are very very happy! Smile will just get bigger & Bigger on rises to all the levels to 10p & beyond! Have a very good evening! 😀

& 3.15p paid.

News getting closer! 25K buy at 3.10p for 805203 shares. Also nice feeeeeling to be 40% up! 🤣 😂

is good money which should double in few months. No brainer.

all. Someone picking up bargain basement @ 3p; good to see. FDA news soon.

to see buys in ISDX as well. It can feel uneasy seeing small drop but imo holding for next few months is the key. Thelix has summed it up well!

By the time most get out of their sofa & reliase potential here, we could be 40p+. Curently we are softly closing up on 30p.

again today. I have topped up further.

HOC to be in now as gold also rising!

Buys currently going thro in ISDX.

GM to you. Q1 FDA news due. So anytime now as we are mid Feb now. Highlights Dosing commenced in the Phase I exploratory pharmacokinetic (PK) study designed to confirm improved release properties of OXPzero™ Ibuprofen Confirmation that FDA responses on US regulatory pathway for OXPzero™ Ibuprofen over-the-counter (OTC) and prescription (Rx) categories are expected during Q1 2017 Successful manufacturing process validation of OXPzero™ Ibuprofen at intermediate scale Further NSAID*, OXPzero™ Ketorolac, successfully synthesised at laboratory scale Remains well funded to pursue strategy, with circa £21.9 million net cash at year end Plenty of news to come so add when ever one can.

Druckenmiller is back and now he’s bullish on the yellow metal! That's how big boys play the game. Bring metal down & take position again. Do we follow same? This is up from near £2 to £2.70p in a month. Invitation was there to take position. Looking forward to £3+